OncoMatch/Clinical Trials/NCT07447050
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Is NCT07447050 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Riluzole for breast cancer.
Treatment: Riluzole — This is a phase II single-arm, Phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining efficacy of riluzole in preventing cognitive dysfunction in subjects with cancer, who are receiving chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Sarcoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Renal Cell Carcinoma
Prostate Cancer
Urothelial Carcinoma
Testicular Germ Cell Tumor
Penile Carcinoma
Endometrial Cancer
Cervical Cancer
Lab requirements
Liver function
ast and/or alt < 3 x upper limit normal (uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07447050 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages